ArticleBMC infectious diseases2025
Capnocytophaga sputigena bacteremia in a nasopharyngeal carcinoma patient with severe neutropenia: a case report.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human Oral-AssociatedMicroorganisms · 2026Review
- A case report of post-arthroscopic knee infection caused by Capnocytophaga sputigena in an anemic patient.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCapnocytophaga sputigena, a fastidious Gram-negative commensal of the human oral flora, rarely causes bloodstream infections but poses significant risks to immunocompromised hosts, particularly those with hematologic malignancies or mucosal barrier injury. CASE PRESENTATION: We report a rare case of C. sputigena bacteremia in a 51-year-old man with epidermal growth factor receptor (EGFR)-positive nasopharyngeal carcinoma (NPC) Stage IV (cT3N2M1), as confirmed by immunohistochemistry. The patient, who was undergoing chemotherapy, presented with severe neutropenia (absolute neutrophil count 0.04 × 109/L), fever (38.9°C), and oral mucositis. Blood cultures identified slender Gram-negative bacilli, which were confirmed as C. sputigena using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) and 16S rDNA sequencing. Initial empirical therapy with meropenem led to clinical improvement, and antimicrobial therapy was subsequently de-escalated to ceftazidime. The patient was eventually discharged in stable condition.
conclusionsThis case underscores that C. sputigena can act as an opportunistic pathogen in solid tumor patients with therapy-induced mucosal damage and highlights the critical importance of meticulous oral care and advanced microbiological diagnostics in managing immunocompromised individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.